Subscribe
shutterstock_663686986_kristi-blokhin
Kristi Blokhin / Shutterstock.com
22 February 2022Americas

Canada delivers landmark ruling in favour of big pharma

The  Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Big pharma steps up access, but uneven progress made: report
16 November 2022   Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.


Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

Editor's picks

Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024

More on this story

Big Pharma
Big pharma steps up access, but uneven progress made: report
16 November 2022   Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

More on this story

Big Pharma
Big pharma steps up access, but uneven progress made: report
16 November 2022   Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

More features

Astellas defends blockbuster cancer treatment patent
Regeneron denied safe harbour defence in COVID-19 drug dispute
How to navigate patent term adjustment in China
Moderna wins reprieve in COVID-19 vaccine dispute
Boehringer sues Indian manufacturer over diabetes drug generic
UK judge ends J&J unit’s hopes of reviving Stelara patent
‘It was like starting all over again’: Tobias Wuttke
‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards